Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1981 2
1982 2
1983 2
1984 4
1985 1
1986 2
1987 2
1988 3
1989 1
1990 5
1991 6
1992 12
1993 13
1994 11
1995 13
1996 13
1997 12
1998 20
1999 17
2000 24
2001 13
2002 33
2003 44
2004 54
2005 58
2006 55
2007 56
2008 85
2009 69
2010 92
2011 127
2012 133
2013 174
2014 167
2015 170
2016 151
2017 170
2018 226
2019 249
2020 326
2021 362
2022 503
2023 464
2024 556
2025 630
2026 513
2027 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,129 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean geng f[Author] (1,079 results)?
Injury Prevention.
Coyner KJ, Anderson A, Mallery CR, Zeng F, Schafer A. Coyner KJ, et al. Among authors: zeng f. Clin Sports Med. 2026 Jul;45(3):483-492. doi: 10.1016/j.csm.2025.10.002. Epub 2025 Dec 3. Clin Sports Med. 2026. PMID: 42209054 Review.
Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy.
Yao L, Zhao D, Meng Y, Liu Y, Su H, Chen D, Guo Z, Li D, Li L, Zhou Q, Xu S, Zeng F, Chen X, Zhou L, Deng G. Yao L, et al. Among authors: zeng f. Cell Rep Med. 2026 Aug 18;7(8):102928. doi: 10.1016/j.xcrm.2026.102928. Epub 2026 Jul 22. Cell Rep Med. 2026. PMID: 42486098 Free PMC article.
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.
Zeng L, Ruan Z, Yan H, Qin H, Zeng Z, Zou C, Huang Z, Jiang W, Dai J, Xu S, Song L, Chen Y, Zhang Y, Zeng F, Wei S, Chen S, Liu L, Xiong Y, Wang Z, Deng J, Zhang X, Sun Y, Yang D, Zhou C, Yang H, Li Y, Deng L, Xu Q, Fang C, Chen X, Wang J, Li T, Zhang G, Zhou H, Yang N, Zhang Y. Zeng L, et al. Among authors: zeng f. Nat Commun. 2025 Dec 15;17(1):567. doi: 10.1038/s41467-025-67262-x. Nat Commun. 2025. PMID: 41398162 Free PMC article. Clinical Trial.
5,129 results